News

Measuring cognition in reMYND’s Tau animal models

24-06-2015
reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age and a strong correlation of Tau pathology with the motor phenotype.

IWT supports reMYND in developing a cure for Type 1 Diabetes

23-06-2015
Press release | reMYND NV today announced that it has received a grant from IWT, the Flemish agency for Innovation by Science and Technology, to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).

Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model

06-03-2015
Two-photon imaging allows tracking the formation of Tau aggregates  in the same brain-region of a live animal over the course of time. This makes it possible to study the effects of treatment longitudinally in vivo.

Transgenic mouse model of combined Abeta and tau pathology

17-12-2014
The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.

Robust LTP measurements in Tau models

12-11-2014
Long term potentiation (LTP), a reflection of dendritic spine density and synaptic plasticity, is gaining importance as a functional ex-vivo or even in-vivo read-out related to learning and memory.

Pages